EJHaem · 2025
Safe and Efficacious Use of Low-Dose Rituximab in Postpubertal Paediatric Patients With Immune Thrombocytopenia.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Darlow Jennifer, Gurumurthy Gerard, Jeffreys Nathan, Reynolds Lianna, Deshani Vismay, Grainger John
Аннотация
BACKGROUND: Rituximab, a CD20 monoclonal antibody, is used in chronic/refractory immune thrombocytopenia (ITP). Standard dosing is 375 mg/m2 weekly for 4 weeks alongside dexamethasone. A lower dose of Rituximab at 100 mg weekly demonstrates comparable efficacy that is well tolerated. This study evaluates lower-dose Rituximab with dexamethasone in postpubertal pediatric ITP patients.
METHODS: Patients treated with 100 mg weekly Rituximab for 4 weeks alongside dexamethasone at 10 mg/m2 on days 1-5 and 21-25 were assessed for response and safety.
RESULTS: Of the 10 patients treated, six responded completely, one partially and three showed no response. Four responders maintained their response over 2 years. One Rituximab-related infusion reaction and one Dexamethasone-related adverse event were reported.
CONCLUSION: Rituximab 100 mg weekly may be non-inferior to 375 mg/m2 weekly for paediatric patients.
METHODS: Patients treated with 100 mg weekly Rituximab for 4 weeks alongside dexamethasone at 10 mg/m2 on days 1-5 and 21-25 were assessed for response and safety.
RESULTS: Of the 10 patients treated, six responded completely, one partially and three showed no response. Four responders maintained their response over 2 years. One Rituximab-related infusion reaction and one Dexamethasone-related adverse event were reported.
CONCLUSION: Rituximab 100 mg weekly may be non-inferior to 375 mg/m2 weekly for paediatric patients.